FDA Brief

Warning letters Drugs

FDA warning letter to

Great India Overseas Pvt. Ltd. dba Silkrute

High riskIssued Jun 17Posted Jun 23Center for Drug Evaluation and Research (CDER)

FDA warns Silkrute over unapproved new drugs sold on its website, including ProGlan, Cordiagra, and Prost Aid.

What happened

FDA reviewed Silkrute's website in May 2026 and found ProGlan Capsules, Cordiagra, and Prost Aid Tablet marketed with claims to treat prostate problems, erectile dysfunction, and urinary tract infection or BPH. FDA says the products are unapproved new drugs because no FDA-approved application is in effect, and ProGlan's labeling uses an FDA logo with “APPROVED.”

What FDA found

  1. The website claims for ProGlan, Cordiagra, and Prost Aid show they are intended to treat disease or affect body function, making them drugs.

    FD&C Act section 201(g)(1), 21 U.S.C. 321(g)(1)
  2. FDA says the three products are “new drugs” not generally recognized as safe and effective and have no approved FDA application.

    FD&C Act sections 201(p) and 505(a), 21 U.S.C. 321(p) and 355(a)
  3. FDA says selling these unapproved new drugs in interstate commerce is prohibited.

    FD&C Act sections 301(d) and 505(a), 21 U.S.C. 331(d) and 355(a)
  4. ProGlan's label or website uses an FDA logo with “APPROVED,” misleadingly suggesting FDA approval or endorsement.

    FD&C Act section 502(a), 21 U.S.C. 352(a)
  5. FDA says selling this misbranded drug in interstate commerce is prohibited.

    FD&C Act section 301(a), 21 U.S.C. 331(a)

What FDA wants

FDA tells the company to respond in writing within 15 business days with the steps taken to correct the violations, steps to prevent recurrence, and related documentation, referencing 729065.

Who should pay attention

  • online sellers of ayurvedic or herbal supplements
  • dietary supplement brands making disease-treatment claims
  • companies using FDA logos or approval claims in product marketing

This is a summary. Read the original letter on fda.gov.

Similar letters to other companies

  1. Natuzem

    FDA warned Mexico-based Natuzem for selling unapproved new drugs, including Reumofan Plus, to U.S. consumers online.

    High risk
  2. RonanRx, Inc. dba RonanRx

    FDA says RonanRx's website and X posts misbrand compounded semaglutide and tirzepatide with false or misleading claims.

    Low
  3. Calibrate IV Hydration

    FDA told Calibrate IV Hydration its umbilical cord and exosome IV products are unapproved drugs and unlicensed biologics.

    High risk
  4. Best Chinese Medicines LLC

    FDA warned Best Chinese Medicines LLC that five herbal products sold online are unapproved new drugs because their labeling claims to treat diseases.

    High risk